What Progress Have We Made in Managing Inflammatory Breast Cancer?
Overview
Affiliations
Inflammatory breast cancer (IBC) is a rare and aggressive form of the disease. It is diagnosed based on clinical signs of a rapidly enlarging, tender, erythematous, edematous breast that often presents without an underlying breast mass. IBC historically was considered a uniformly fatal disease. With the advent of multimodality treatments including primary systemic chemotherapy, surgery, and radiation therapy, approximately one-third of women diagnosed with IBC will become long-term survivors. This review examines the limitations of the current definition of IBC, explores our current understanding of the biology of IBC, and reviews the many exciting advances in locoregional and systemic treatment of IBC.
Hirko K, Soliman A, Banerjee M, Ruterbusch J, Harford J, Merajver S Breast J. 2013; 20(2):185-91.
PMID: 24372839 PMC: 4208694. DOI: 10.1111/tbj.12234.
On how CCN6 suppresses breast cancer growth and invasion.
Huang W, Pal A, Kleer C J Cell Commun Signal. 2011; 6(1):5-10.
PMID: 21842227 PMC: 3271195. DOI: 10.1007/s12079-011-0148-9.
Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas.
Goldfarb J, Pippen J Proc (Bayl Univ Med Cent). 2011; 24(2):86-8.
PMID: 21566749 PMC: 3069510. DOI: 10.1080/08998280.2011.11928688.
Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B Clin Cancer Res. 2009; 16(1):45-55.
PMID: 20028757 PMC: 2874875. DOI: 10.1158/1078-0432.CCR-09-1630.
Chen J, Mehta R, Nalcioglu O, Su M Ann Surg Oncol. 2008; 15(12):3609-13.
PMID: 18807091 PMC: 2613188. DOI: 10.1245/s10434-008-0141-6.